Loading...

We've got a brand new version of Simply Wall St! Try it out

Veru

Nasdaq:VERU
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VERU
Nasdaq
$125M
Market Cap
  1. Home
  2. US
  3. Household
Company description

Veru Inc., an oncology and urology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care, and urology specialty pharmaceuticals. The last earnings update was 96 days ago. More info.


Add to Portfolio Compare Print
VERU Share Price and Events
7 Day Returns
-5%
NasdaqCM:VERU
2.2%
US Personal Products
0.3%
US Market
1 Year Returns
34.3%
NasdaqCM:VERU
20.5%
US Personal Products
12.5%
US Market
VERU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Veru (VERU) -5% -7.2% 0% 34.3% 94.9% -54.6%
US Personal Products 2.2% -1.1% 5.5% 20.5% 54.3% 59.2%
US Market 0.3% 4.1% 5.6% 12.5% 39.4% 44.7%
1 Year Return vs Industry and Market
  • VERU outperformed the Personal Products industry which returned 20.5% over the past year.
  • VERU outperformed the Market in United States of America which returned 12.5% over the past year.
Price Volatility
VERU
Industry
5yr Volatility vs Market

VERU Value

 Is Veru undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Veru to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Veru.

NasdaqCM:VERU Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:VERU
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.68 (1 + (1- 21%) (8.79%))
0.818
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.818 * 5.96%)
7.6%

Discounted Cash Flow Calculation for NasdaqCM:VERU using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Veru is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqCM:VERU DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.6%)
2020 -24.40 Analyst x1 -22.68
2021 -15.30 Analyst x1 -13.21
2022 -17.00 Analyst x1 -13.65
2023 -6.00 Analyst x1 -4.48
2024 16.50 Analyst x1 11.44
2025 25.61 Est @ 55.19% 16.50
2026 35.71 Est @ 39.45% 21.38
2027 45.86 Est @ 28.44% 25.52
2028 55.37 Est @ 20.72% 28.63
2029 63.85 Est @ 15.33% 30.69
Present value of next 10 years cash flows $80.00
NasdaqCM:VERU DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $63.85 × (1 + 2.73%) ÷ (7.6% – 2.73%)
$1,346.28
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,346.28 ÷ (1 + 7.6%)10
$647.01
NasdaqCM:VERU Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $80.00 + $647.01
$727.01
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $727.01 / 65.04
$11.18
NasdaqCM:VERU Discount to Share Price
Calculation Result
Value per share (USD) From above. $11.18
Current discount Discount to share price of $1.92
= -1 x ($1.92 - $11.18) / $11.18
82.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Veru is available for.
Intrinsic value
>50%
Share price is $1.92 vs Future cash flow value of $11.18
Current Discount Checks
For Veru to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Veru's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Veru's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Veru's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Veru's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:VERU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.28
NasdaqCM:VERU Share Price ** NasdaqCM (2019-11-12) in USD $1.92
United States of America Personal Products Industry PE Ratio Median Figure of 21 Publicly-Listed Personal Products Companies 17.08x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Veru.

NasdaqCM:VERU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:VERU Share Price ÷ EPS (both in USD)

= 1.92 ÷ -0.28

-6.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Veru is loss making, we can't compare its value to the US Personal Products industry average.
  • Veru is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Veru's expected growth come at a high price?
Raw Data
NasdaqCM:VERU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
58.2%per year
United States of America Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.56x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Veru, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Veru's assets?
Raw Data
NasdaqCM:VERU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.54
NasdaqCM:VERU Share Price * NasdaqCM (2019-11-12) in USD $1.92
United States of America Personal Products Industry PB Ratio Median Figure of 43 Publicly-Listed Personal Products Companies 2.65x
United States of America Market PB Ratio Median Figure of 5,066 Publicly-Listed Companies 1.74x
NasdaqCM:VERU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:VERU Share Price ÷ Book Value per Share (both in USD)

= 1.92 ÷ 0.54

3.58x

* Primary Listing of Veru.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Veru is overvalued based on assets compared to the US Personal Products industry average.
X
Value checks
We assess Veru's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Veru has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VERU Future Performance

 How is Veru expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Veru expected to grow at an attractive rate?
  • Veru's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Veru's earnings growth is expected to exceed the United States of America market average.
  • Veru's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:VERU Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:VERU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 58.2%
NasdaqCM:VERU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 35.9%
United States of America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 17.7%
United States of America Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:VERU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:VERU Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30 178 36 32 2
2023-09-30 124 14 23 3
2022-09-30 87 2 3 2
2021-09-30 41 2 -5 3
2020-09-30 36 -6 -10 4
2019-11-12
2019-09-30 32 5 -12 4
NasdaqCM:VERU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 28 -7 -17
2019-03-31 24 -11 -22
2018-12-31 20 -13 -22
2018-09-30 16 -12 -24
2018-06-30 14 -8 -21
2018-03-31 13 -2 -14
2017-12-31 13 0 -11
2017-09-30 14 1 -9
2017-06-30 14 0 -6
2017-03-31 15 -1 -4
2016-12-31 17 0 -3
2016-09-30 22 -2 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Veru's earnings are expected to grow significantly at over 20% yearly.
  • Veru's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:VERU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Veru Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:VERU Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30 0.77 1.06 0.47 2.00
2023-09-30 0.41 0.63 0.07 3.00
2022-09-30 -0.06 0.20 -0.27 3.00
2021-09-30 -0.20 -0.02 -0.46 3.00
2020-09-30 -0.15 -0.10 -0.23 3.00
2019-11-12
2019-09-30 -0.19 -0.18 -0.20 4.00
NasdaqCM:VERU Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.28
2019-03-31 -0.38
2018-12-31 -0.39
2018-09-30 -0.44
2018-06-30 -0.40
2018-03-31 -0.30
2017-12-31 -0.29
2017-09-30 -0.25
2017-06-30 -0.19
2017-03-31 -0.14
2016-12-31 -0.09
2016-09-30 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Veru will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Veru's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Veru has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VERU Past Performance

  How has Veru performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Veru's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Veru does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Veru's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Veru's 1-year growth to the US Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Veru's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Veru Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:VERU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 28.28 -16.88 14.11 13.17
2019-03-31 24.05 -22.03 14.59 12.09
2018-12-31 19.65 -21.83 14.58 11.25
2018-09-30 15.86 -23.94 14.32 10.85
2018-06-30 14.35 -20.69 14.11 9.22
2018-03-31 13.17 -13.55 13.27 5.74
2017-12-31 13.00 -11.49 12.00 4.86
2017-09-30 13.66 -8.60 11.50 3.08
2017-06-30 13.53 -5.68 9.95 1.68
2017-03-31 14.77 -4.32 8.29 1.40
2016-12-31 17.14 -2.51 8.28 0.27
2016-09-30 22.13 0.34 8.75 0.10
2016-06-30 25.72 2.80 10.20 0.32
2016-03-31 27.97 3.40 11.85 0.29
2015-12-31 34.18 5.03 12.76 0.22
2015-09-30 32.60 4.35 12.13 0.22
2015-06-30 31.00 3.08 12.35 0.01
2015-03-31 31.09 3.07 11.32 0.01
2014-12-31 24.46 1.77 9.46 0.01
2014-09-30 24.49 2.43 9.19 0.01
2014-06-30 23.73 9.59 6.36
2014-03-31 23.11 9.16 6.87
2013-12-31 28.24 12.27 7.44
2013-09-30 31.46 14.34 7.71 0.00
2013-06-30 36.58 15.94 9.75
2013-03-31 37.96 17.76 9.58
2012-12-31 36.31 16.17 9.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Veru has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Veru has efficiently used its assets last year compared to the US Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Veru improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Veru's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Veru has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VERU Health

 How is Veru's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Veru's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Veru is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Veru's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Veru's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Veru Company Filings, last reported 4 months ago.

NasdaqCM:VERU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 34.74 10.97 8.04
2019-03-31 33.54 10.90 5.90
2018-12-31 36.88 9.64 8.98
2018-09-30 29.48 11.15 3.76
2018-06-30 35.87 11.22 5.58
2018-03-31 41.33 10.11 8.97
2017-12-31 44.75 0.00 3.57
2017-09-30 48.45 0.00 3.28
2017-06-30 50.79 0.00 2.67
2017-03-31 51.52 0.00 1.24
2016-12-31 53.22 0.00 3.49
2016-09-30 33.93 0.00 2.39
2016-06-30 35.51 0.00 3.21
2016-03-31 34.85 0.00 2.79
2015-12-31 34.72 0.00 3.67
2015-09-30 33.13 0.00 4.11
2015-06-30 32.38 0.00 2.62
2015-03-31 31.06 0.00 2.93
2014-12-31 29.26 0.00 4.57
2014-09-30 28.07 0.00 5.80
2014-06-30 28.97 0.00 4.14
2014-03-31 27.75 0.00 5.94
2013-12-31 29.27 0.00 7.99
2013-09-30 31.40 0.00 8.92
2013-06-30 26.73 0.00 11.88
2013-03-31 25.89 0.00 6.15
2012-12-31 24.48 0.00 4.28
  • Veru's level of debt (31.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Veru's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Veru has sufficient cash runway for 1.1 years based on current free cash flow.
  • Veru has less than a year of cash runway if free cash flow continues to grow at historical rates of 94.8% each year.
X
Financial health checks
We assess Veru's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Veru has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VERU Dividends

 What is Veru's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Veru dividends.
If you bought $2,000 of Veru shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Veru's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Veru's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:VERU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:VERU Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2019-11-12
2019-09-30
NasdaqCM:VERU Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2016-02-02 0.000 0.000
2015-12-02 0.000 0.000
2015-12-01 0.000 0.000
2015-07-30 0.000 0.000
2015-04-30 0.000 0.000
2015-02-03 0.000 0.000
2014-12-02 0.000 0.000
2014-07-31 0.000 0.000
2014-03-24 0.280 4.736
2013-12-16 0.280 3.751
2013-10-04 0.280 3.022
2013-08-01 0.280 3.046
2013-03-27 0.280 3.227
2013-01-03 0.240 3.327
2012-10-05 0.240 3.353
2012-07-13 0.240 3.773
2012-03-27 0.240 4.277
2012-01-05 0.200 3.872
2011-10-07 0.200 4.471
2011-07-15 0.200 4.632
2011-04-13 0.200 4.065
2011-01-14 0.200 4.007
2010-10-08 0.200 3.437
2010-07-23 0.200 4.079
2010-04-12 0.200 3.489
2010-01-19 0.200 3.299

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Veru has not reported any payouts.
  • Unable to verify if Veru's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Veru's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Veru has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Veru's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Veru afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Veru has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VERU Management

 What is the CEO of Veru's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mitch Steiner
COMPENSATION $740,266
AGE 58
TENURE AS CEO 3.1 years
CEO Bio

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 & has been its Chairman since November 2018. Dr. Steiner Co-Founded Aspen Park Pharmaceuticals, Inc. and served as its Chief Executive Officer and President. Dr. Steiner Co-founded GTx Inc. in September 1997 and served as its Vice Chairman and Chief Executive Officer from September 1997 to April 3, 2014. He had been Member of Board of Advisors at arGentis Pharmaceuticals, LLC since August 2010. He serves as a Member of Financial Advisory Board at MB Venture Partners and MB Venture, LLC. Dr. Steiner served numerous Academic appointments, including Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee. Dr. Steiner simultaneously had an appointment as Assistant Professor of Urology, Cell Biology and Pathology while at Vanderbilt University School of Medicine. He served as Vice Chairman of Aspen Park Pharmaceuticals, Inc. since July 2014 until October 2016 and served as its Director. From 2014 to 2016, Dr. Steiner was a consultant and then the President of Urology and member of senior management of OPKO Health, Inc. He conducted gene therapy clinical trials for prostate cancer in which he has served as a consultant and Principal Investigator. Dr. Steiner has conducted independent laboratory research in cancer since 1980 and has been the recipient of grants from the National Institutes of Health and the Department of Defense. Dr. Steiner has authored more than 200 abstracts and publications and he serves on the Editorial Board of several peer reviewed medical publications in the fields of urology and oncology. Dr. Steiner is Board Certified in Urology (February 1997) and a Fellow of the American College of Surgeons (October 2000). Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee in 1986. He obtained a Molecular Biology Postdoctoral fellowship as an American Foundation for Urologic Disease Scholar from Vanderbilt University from 1986 to 1995. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.

CEO Compensation
  • Mitch's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mitch's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Veru management team in years:

1.7
Average Tenure
58
Average Age
  • The average tenure for the Veru management team is less than 2 years, this suggests a new team.
Management Team

Mitch Steiner

TITLE
Chairman
COMPENSATION
$740K
AGE
58
TENURE
3.1 yrs

Harry Fisch

TITLE
Vice Chairman & Chief Corporate Officer
COMPENSATION
$277K
AGE
60
TENURE
3.1 yrs

Michele Greco

TITLE
CFO, Executive VP of Finance & Chief Administrative Officer
COMPENSATION
$522K
AGE
60
TENURE
1.8 yrs

K. Barnette

TITLE
Chief Scientific Officer
COMPENSATION
$401K
AGE
51

Philip Greenberg

TITLE
Executive VP of Legal & Secretary
TENURE
1 yrs

Kevin Gilbert

TITLE
Executive Vice President of Corporate Development

Phillip Kuhn

TITLE
Executive Vice President of Strategy & Commercial

Domingo Rodriguez

TITLE
Executive Vice President of Clinical Operations
AGE
57
TENURE
1.6 yrs

Gary Bird

TITLE
Senior Vice President of Quality Oversight
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Veru board of directors in years:

2.7
Average Tenure
60.5
Average Age
  • The average tenure for the Veru board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mitch Steiner

TITLE
Chairman
COMPENSATION
$740K
AGE
58
TENURE
1 yrs

Harry Fisch

TITLE
Vice Chairman & Chief Corporate Officer
COMPENSATION
$277K
AGE
60

Jesus Socorro

TITLE
Independent Director
COMPENSATION
$60K
AGE
43
TENURE
2.7 yrs

Andy Love

TITLE
Board Observer
AGE
75
TENURE
3.1 yrs

Mario Eisenberger

TITLE
Independent Director
COMPENSATION
$55K
AGE
69
TENURE
3.1 yrs

Michael Rankowitz

TITLE
Independent Director
COMPENSATION
$70K
AGE
61
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Veru individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
04. Sep 19 Buy Harry Fisch Individual 03. Sep 19 03. Sep 19 10,000 $1.93 $19,250
03. Sep 19 Buy Harry Fisch Individual 30. Aug 19 30. Aug 19 4,000 $1.97 $7,880
30. Aug 19 Buy Harry Fisch Individual 29. Aug 19 29. Aug 19 7,000 $1.92 $13,440
22. Aug 19 Buy Michele Greco Individual 20. Aug 19 20. Aug 19 20,000 $1.84 $36,736
12. Aug 19 Buy Jesus Socorro Individual 12. Aug 19 12. Aug 19 10,000 $1.95 $19,506
18. Mar 19 Buy Harry Fisch Individual 15. Mar 19 15. Mar 19 3,000 $1.47 $4,410
13. Mar 19 Buy Harry Fisch Individual 13. Mar 19 13. Mar 19 3,500 $1.47 $5,145
07. Mar 19 Buy Harry Fisch Individual 06. Mar 19 06. Mar 19 3,000 $1.43 $4,290
06. Mar 19 Buy Harry Fisch Individual 05. Mar 19 05. Mar 19 3,500 $1.47 $5,145
01. Mar 19 Buy Harry Fisch Individual 27. Feb 19 27. Feb 19 3,400 $1.39 $4,726
27. Feb 19 Buy Harry Fisch Individual 26. Feb 19 26. Feb 19 5,000 $1.27 $6,350
26. Feb 19 Buy Harry Fisch Individual 25. Feb 19 25. Feb 19 3,000 $1.32 $3,960
25. Feb 19 Buy Harry Fisch Individual 22. Feb 19 22. Feb 19 6,000 $1.30 $7,800
22. Feb 19 Buy Harry Fisch Individual 21. Feb 19 21. Feb 19 5,000 $1.35 $6,750
20. Feb 19 Buy Harry Fisch Individual 19. Feb 19 19. Feb 19 5,000 $1.36 $6,795
16. Feb 19 Buy Harry Fisch Individual 15. Feb 19 15. Feb 19 13,681 $1.36 $18,654
20. Dec 18 Buy Harry Fisch Individual 18. Dec 18 18. Dec 18 30,000 $1.42 $42,672
19. Dec 18 Buy Gary Barnette Individual 17. Dec 18 18. Dec 18 100,000 $1.51 $146,160
X
Management checks
We assess Veru's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Veru has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VERU News

Simply Wall St News

Did You Manage To Avoid Veru's (NASDAQ:VERU) 50% Share Price Drop?

Check out our latest analysis for Veru Given that Veru didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … We doubt many shareholders are delighted with this share price performance. … NasdaqCM:VERU Income Statement, August 15th 2019 We like that insiders have been buying shares in the last twelve months.

Simply Wall St -

Veru (NASDAQ:VERU) Has Us Worried With Its Last Reported Debt Levels

NasdaqCM:VERU Historical Debt, July 24th 2019 A Look At Veru's Liabilities According to the last reported balance sheet, Veru had liabilities of US$11.3m due within 12 months, and liabilities of US$6.20m due beyond 12 months. … Because it carries more debt than cash, we think it's worth watching Veru's balance sheet over time. … When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt.

Simply Wall St -

Should You Worry About Veru Inc.'s (NASDAQ:VERU) CEO Pay Cheque?

First, this article will compare CEO compensation with compensation at similar sized companies. … See our latest analysis for Veru How Does Mitch Steiner's Compensation Compare With Similar Sized Companies? … We took a group of companies with market capitalizations below US$200m, and calculated the median CEO total compensation to be US$465k.

Simply Wall St -

What Kind Of Shareholder Appears On The Veru Inc.'s (NASDAQ:VERU) Shareholder Register?

See our latest analysis for Veru NasdaqCM:VERU Ownership Summary, May 20th 2019 What Does The Institutional Ownership Tell Us About Veru? … We can see that Veru does have institutional investors; and they hold 8.7% of the stock. … Insider Ownership Of Veru The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Did Changing Sentiment Drive Veru's (NASDAQ:VERU) Share Price Down A Painful 81%?

Given that Veru didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … In the last five years Veru saw its revenue shrink by 15% per year.

Simply Wall St -

Does Veru Inc.'s (NASDAQ:VERU) CEO Salary Compare Well With Others?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Mitch Steiner's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m

Simply Wall St -

Are Veru Inc.'s (NASDAQ:VERU) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Veru Inc. … However, an important fact which most ignore is: how financially healthy is the business? … Since VERU is loss-making right now,

Simply Wall St -

Can We See Significant Insider Ownership On The Veru Inc. (NASDAQ:VERU) Share Register?

Veru is a smaller company with a market capitalization of US$92m, so it may still be flying under the radar of many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that. … We can zoom in on the different ownership groups, to learn more about VERU

Simply Wall St -

Who Has Been Buying Veru Inc. (NASDAQ:VERU) Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … In the last twelve months, the biggest single purchase by an insider was when Gary Barnette bought US$146k worth of shares at a price of US$1.51 per share. … That means that even when the share price was higher, an insider wanted to purchase shares.

Simply Wall St -

How Does Investing In Veru Inc (NASDAQ:VERU) Impact The Volatility Of Your Portfolio?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

VERU Company Info

Description

Veru Inc., an oncology and urology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care, and urology specialty pharmaceuticals. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST* 4% benzocaine WIPES for the prevention of premature ejaculation. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist, planned Phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN*, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its customers primarily include international agencies, non-government organizations, and ministries of health and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida with offices in London, United Kingdom and Kuala Lumpur, Malaysia.

Details
Name: Veru Inc.
VERU
Exchange: NasdaqCM
Founded:
$124,873,434
65,038,247
Website: http://www.verupharma.com
Address: Veru Inc.
48 NW 25th Street,
Suite 102,
Miami,
Florida, 33127,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM VERU Common Stock Nasdaq Capital Market US USD 19. Jul 1990
DB FMW Common Stock Deutsche Boerse AG DE EUR 19. Jul 1990
Number of employees
Current staff
Staff numbers
171
Veru employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/12 23:34
End of day share price update: 2019/11/12 00:00
Last estimates confirmation: 2019/10/03
Last earnings filing: 2019/08/08
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.